Compare · NEOG vs VNRX
NEOG vs VNRX
Side-by-side comparison of Neogen Corporation (NEOG) and VolitionRX Limited (VNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NEOG and VNRX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NEOG is the larger of the two at $2.68B, about 472.7x VNRX ($5.7M).
- Over the past year, NEOG is up 101.0% and VNRX is down 98.0% - NEOG leads by 199.0 points.
- NEOG has been more active in the news (17 items in the past 4 weeks vs 3 for VNRX).
- NEOG has more recent analyst coverage (6 ratings vs 4 for VNRX).
- Company
- Neogen Corporation
- VolitionRX Limited
- Price
- $11.82-3.67%
- $0.18-4.52%
- Market cap
- $2.68B
- $5.7M
- 1M return
- -7.84%
- -34.95%
- 1Y return
- +101.02%
- -97.97%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- AMEX
- IPO
- 1989
- 2015
- News (4w)
- 17
- 3
- Recent ratings
- 6
- 4
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
VolitionRX Limited
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.
Latest NEOG
- SEC Form 4 filed by Neogen Corporation
- Neogen Outlines Strategy for Growth, Innovation and Margin Expansion at 2026 Investor Day
- SEC Form 10-Q filed by Neogen Corporation
- SEC Form 8-K filed by Neogen Corporation
- SEC Form 8-K filed by Neogen Corporation
- Neogen Reports First-Quarter Financial Results for Fiscal Year 2027
- Neogen Announces Strategic Collaboration with Hinalea Imaging to Advance Digital Food Safety Solutions
- NEOG Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Neogen (NEOG)
- Director Woteki Catherine E was granted 9,804 units of Restricted Stock Units, increasing direct ownership by 51% to 28,921 units (SEC Form 4)
- Director Wainer Andrea F was granted 9,804 units of Restricted Stock Units, increasing direct ownership by 483% to 11,834 units (SEC Form 4)
Latest VNRX
- Chief Commercial Officer Forterre Gael covered exercise/tax liability with 284 shares, decreasing direct ownership by 2% to 16,284 units (SEC Form 4) (tax liability)
- Chief Operating Officer Michel Gaetan covered exercise/tax liability with 608 shares, decreasing direct ownership by 5% to 12,232 units (SEC Form 4) to cover withholding tax
- VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities
- VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
- VolitionRx Participates in Launch of DETECSEPS Program in France
- VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities
- VolitionRX Limited filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
- SEC Form EFFECT filed by VolitionRX Limited
- Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference